touchONCOLOGY joins Dr Shibani Nicum (University College London, UK) at ESMO 2021 to present the first results of the OCTOVA trial of olaparib compared to weekly paclitaxel or olaparib plus cediranib in patients with platinum-resistant ovarian cancer.
Questions
1. What are the unmet needs in the treatment of ovarian cancer patients who relapse within 12 months of platinum-based chemotherapy? 00:18-01:00)
2. What is the rationale for combining olaparib and cediranib in this indication? (01:08-02:26)
3. Could you tell us a little about the aims, design and patient stratification of the OCTOVA trial? (02:26-03:55)
4. What were the efficacy and safety findings of the trial? (03:55-05:42)
5. What were the conclusions of the investigators, and what future studies are planned? (05:42-06:30)
Disclosures: Shibani Nicum disclosures consulting and advisory services, speaking or writing engagements, public presentations for AstraZeneca, GSK and Clovis, and academic funding from AstraZeneca.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the ESMO 2021 Annual Meeting.
